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Abstract: Vitamin D deficiency has been clearly linked to major chronic diseases associated with
oxidative stress, inflammation, and aging, including cardiovascular and neurodegenerative diseases,
diabetes, and cancer. In particular, the cardiovascular system appears to be highly sensitive to
vitamin D deficiency, as this may result in endothelial dysfunction and vascular defects via multiple
mechanisms. Accordingly, recent research developments have led to the proposal that pharmacological
interventions targeting either vitamin D deficiency or its key downstream effects, including defective
autophagy and abnormal pro-oxidant and pro-inflammatory responses, may be able to limit the onset
and severity of major cerebrovascular diseases, such as stroke and cerebrovascular malformations.
Here we review the available evidence supporting the role of vitamin D in preventing or limiting the
development of these cerebrovascular diseases, which are leading causes of disability and death all
over the world.
Keywords: cerebrovascular disease; stroke; cerebral cavernous malformation (CCM); vitamin D;
oxidative stress; inflammation; endothelial dysfunction; redox homeostasis and signaling; autophagy;
antioxidant and anti-inflammatory defenses
1. Sources, Metabolism, and Pleiotropic Functions of Vitamin D
The term vitamin D refers to a group of lipid-soluble secosteroid compounds with pro-hormone
activities, of which five forms have been described: vitamin D1, D2, D3, D4, and D5. Among these, the
most important for human biology are vitamin D2 (also known as ergocalciferol), which is produced in
plants and fungi from the precursor ergosterol upon exposure to the sun’s ultraviolet B (UVB) rays, and
vitamin D3 (also known as cholecalciferol), which is mainly produced in the skin from the precursor
7-dehydrocholesterol (7-DHC) upon exposure to UVB rays and may also be obtained from animal
sources or dietary supplements. Both vitamins D2 and D3 are transported in the blood by carrier proteins,
mainly by vitamin D binding protein (VDBP), but also by albumin and lipoproteins, and distributed
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to other tissues (primarily the liver). In the liver, they are hydroxylated at C-25 by 25-hydroxylase
enzymes of the cytochrome P450 monooxygenase (CYP) family (mostly but not exclusively CYP2R1
and CYP27A1) to generate the main circulating form of vitamin D: 25-hydroxy-vitamin D (25(OH)D).
The 25(OH)D is then transported by vitamin D binding proteins via the blood to the kidneys, where it is
internalized by renal proximal tubular cells through receptor (megalin)-mediated endocytosis. There it
undergoes a further hydroxylation at C-1 by the mitochondrial 1-alpha-hydroxylase enzyme (CYP27B1),
to produce the hormonally active form of vitamin D, 1,25-dihydroxy-vitamin D (1,25(OH)2D), which is
responsible for most, if not all of its biological actions [1–4]. Two forms of 1,25(OH)2D exist: 1,25(OH)2D3
(calcitriol) and 1,25(OH)2D2 (ercalcitriol), which are derived from cholecalciferol and ergocalciferol,
respectively. Although the kidneys are the major source of circulating 1,25(OH)2D, a number of other
tissues also express the CYP27B1 enzyme, which uniquely possesses 25(OH)D 1-alpha-hydroxylase
activity. Inactivation and catabolism of both 25(OH)D and 1,25(OH)2D are specifically mediated by the
24-hydroxylase activity of the mitochondrial CYP24A1 enzyme [2].
It is known that 1,25(OH)2D exerts its biological effects by binding to and activating the vitamin
D receptor (VDR), a member of the ligand-regulated nuclear receptor superfamily of transcription
factors widely distributed in the body, expressed by leukocytes [5], endothelial cells [6], astrocytes, and
neurons [7]. Both forms of 1,25(OH)2D can activate the VDR, with similar affinity [2]. Upon activation
by ligand binding, VDR heterodimerizes with the retinoid X receptor (RXR) to form a transcriptionally
active complex [1,8,9]. Formation of the VDR/RXR-heterodimer and its binding to DNA is essential for
the regulation of gene transcription by 1,25(OH)2D [9]. In particular, the VDR/RXR complex binds
vitamin D response elements (VDREs), which are specific promoter sequences. Co-regulator factors
are then recruited to either increase or suppress the transcription of various target genes, including
genes involved in cell proliferation, differentiation, apoptosis, inflammation, and oxidative stress [10]
(Figure 1).
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Figure 1. Vitamin D signaling pathway: 1,25-hydroxyvitamin D (1,25(OH)2D3), also known as calcitriol,
binds to the vitamin D receptor (VDR) and promotes its heterodimerization with the retinoid X
receptor (RXR). The activated VDR/RXR heterodimer then recruits coreg lator complexes and binds
to the vitamin D response elements (VDRE) i the promoters of a large number of gen s involved in
fundamental processes, including cell survival and immune response to injury, thus modulating their
transcription and subsequent effects in a ligand-dependent manner.
Antioxidants 2020, 9, 327 3 of 22
VDR is expressed in more than 30 target tissues in humans [11], and a genome-wide analysis
revealed more than 1000 VDR-specific genomic binding sites in most tissues, suggesting that the
transcriptionally active form of vitamin D influences the expression of many genes likely to be relevant
for human health and disease [12]. Furthermore, lessons from VDR and CYP27B1 null mice indicate
that VDR may act either dependently or independently of 1,25(OH)2D. Thus, multiple receptors and
ligands may participate in the vitamin D endocrine system [1,3,13], in addition to non-genomic actions
via unclear mechanisms [14–16]. Indeed, consistent with the multiple biological functions of the
active form of vitamin D, there is evidence that VDR, which is normally localized in the nucleus and
associated with gene transcription, may also be present in the plasma membrane and mediate rapid
responses to 1,25(OH)2D [11,17].
Vitamin D plays a pivotal role in bone metabolism via calcium and phosphate homeostasis, whereby
it stimulates calcium absorption and reabsorption in the intestine and the kidneys, respectively; it also
contributes to the formation and resorption of bone tissue by promoting the differentiation of osteoblasts
and regulating the effects by other bone-active molecules [16,18].
The ubiquitous expression of the VDR and the CYP27B1 enzyme has led to speculation that vitamin
D may exert physiological roles other than via calcium-phosphate homeostasis (i.e., non-classical
roles) [14,19]. Indeed, the physiological importance of vitamin D extends far beyond the regulation
of calcium homeostasis and bone metabolism. Vitamin D can regulate secretion of some hormones,
including parathyroid hormone (PTH), insulin, and fibroblast growth factor 23 (FGF23), and the effects
on PTH secretion are facilitated by using vitamin D analogues in the clinical treatment of secondary
hyperparathyroidism [20]. Vitamin D also plays an important role in regulating both innate and
adaptive immunity. For example, activated monocytes express CYP27B1 to produce 1,25(OH)2D and
induce antimicrobial peptides, and vitamin D suppresses the proliferation of both B and T lymphocytes,
particularly the T helper-1 and-17 cells that are capable of activating macrophages [14]. On the other
hand, regulatory T lymphocytes are increased by 1,25(OH)2D [21]. Consistent with the suppressive
effect of vitamin D on the adaptive immune system, vitamin D deficiency and VDR polymorphisms
are associated with increased risk of both systemic and organ-specific autoimmune diseases [22].
Moreover, an intervention trial has demonstrated that vitamin D could reduce the incidence of type 1
diabetes mellitus in Finnish infants (a population at high risk of developing autoimmune diseases) [23].
Vitamin D has also been shown to exert anti-proliferative and pro-differentiating effects on many cell
types [24], leading to the evaluation of its potential anticancer activities in human trials [14,25].
The relationship between vitamin D and cardiovascular health has been extensively investigated.
The cardiovascular system appears to be a target for vitamin D, with VDR and 1-alpha hydroxylase
expressed in endothelial and vascular smooth muscle cells and cardiomyocytes, as well as in
macrophages and T-cells, which is also highly relevant to VDR action in the cardiovascular system [26].
Vitamin D regulates the contractility of vascular smooth muscle cells via modulation of calcium
influx, and appears to regulate endothelial function through its antioxidant effects and modulation
of cell survival and autophagy [27,28]. Calcitriol has also been reported to be a negative regulator
of the renin–angiotensin–aldosterone system [29], and thus vitamin D deficiency could contribute to
endothelial dysfunction and the onset of cardiovascular diseases (CVDs). Various studies have indeed
found an association between low circulating levels of 25(OH)D and the onset of hypertension, diabetes
mellitus, and other CVDs [10,30–33]. Vitamin D could perhaps prevent endothelial dysfunction and
atherosclerosis through its antioxidant and anti-inflammatory actions (e.g., inhibition of superoxide
anion generation, modulation of cytokine secretion, and inhibition of monocyte adhesion and
migration) [27,34–37]. More generally, as vitamin D deficiency is associated with many pathologies
resembling those induced by defective autophagy, it has been suggested that autophagy plays a
major role in the multiple health-promoting effects of vitamin D [28,38,39]. Autophagy is an essential
process for cell homeostasis [40], and plays a key role in cellular responses to oxidative stress and
inflammation [41–44].
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2. Anti-inflammatory Properties of Vitamin D
Serum vitamin D levels are inversely associated with interleukin (IL)-6 and high-sensitivity
C-reactive protein (hsCRP) levels in stroke individuals, consistent with a potential anti-inflammatory
role of vitamin D after stroke [45,46]. Experimental evidence has shown that activation of VDR
by calcitriol has immunomodulatory actions [47–50] and prevents leukocyte recruitment to injured
tissues [49,51,52].
Calcitriol exerts its immunomodulatory actions through a variety of mechanisms. It down-regulates
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), a transcription factor involved
in inflammatory gene expression in lymphocytes [53], and can inhibit its activation by reducing DNA
binding of NF-κB [54]. Vitamin D can also dampen inflammation after myocardial injury by inhibiting
the RhoA/Rho-associated protein kinase (ROCK)/NF-κB pathway [55]. Furthermore, the VDR/RXR
complex binds to the nuclear factor of activated T cells (NFAT) binding site of the IL-2 promoter
and inhibits NFAT activity in T cells, thus blocking T cell proliferation [56] and leading to reduced
expression of IL-17A [48]. Calcitriol can modulate the phenotype of T cells by downregulating Janus
kinase (JAK)–signal transducer and activator of transcription (STAT) signaling, which is critical for the
development of pathogenic T helper (Th) cells, such as Th1 and Th17 cells [57–59], gamma-delta (γδ)
T cells [60], and their cytokine production [61]. Moreover, calcitriol can promote the polarization of
anti-inflammatory Th2 [62] and T regulatory (Treg) cells [63], thus inhibiting inflammation-driven injury.
Lastly, calcitriol can promote the generation of tolerogenic dendritic cells [64,65] and prevent the
release of pro-inflammatory cytokines from monocytes/macrophages via inhibition of the p38 MAP
kinase [49,66]. Likewise, it can inhibit atherosclerosis by promoting polarization of macrophages to an
M2-phenotype [67]. Calcitriol can similarly exert an anti-inflammatory action on human microglia
by facilitating M2 differentiation and upregulation of the anti-inflammatory toll-like receptor (TLR)
10 [68]. Furthermore, calcitriol reduces the expression of pro-inflammatory cytokines via promoting
induction of the suppressor of cytokine signaling-3 (SOCS3) by IL-10 [69] (Figure 2A).
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Figure 2. Vitamin D pleiotropic effects on anti-inflammatory (A) and antioxidant (B) signaling pathways
and mechanisms (see text for details). FoxO (Forkhead box-O); FoxP (Forkhead box-P);; JAK (Janus
kinase); IL (interleukin); INFγ (interferon-gamma); MAPK (mitogen-activated protein kinase); mTOR
(mammalian target of rapamycin); NFAT (nuclear factor of a tivated T cells); NF-κB (nuclear factor
kappa-light-chain-enhancer of activated B cells); NOX (NADPH oxidase); Nrf2 (nuclear factor ryth oid
2-related factor 2); RhoA (RhoA GTPase); ROCK (Rho-associated protein kinase); ROS (re ctive oxygen
specie ); SIRT1 (Sirtuin 1); SOCS3 (suppressor of cytokine signaling-3); SOD (superoxide dismutase);
STAT (signal transducer and activator of tr nscription); TLR (toll-like receptor); TNFα (tumor necrosis
factor alpha); γδ T (ga ma-delta T cells); M1 (M1 macrophages); Th (T helper cells); tolDCs (tolerogenic
dendritic cells); Treg (regulatory T cells).
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Inflammation is well established to be a key contributing factor in secondary brain injury after
ischemic stroke, making this process a rational target for new therapies [70]. We recently explored
the effect of experimentally elevating levels of vitamin D in vitamin D-replete mice [50], analogous to
high-dose supplementation regimes in humans [71,72]. Acute supplementation of vitamin D reduced
infarct volume by ~50%, reduced the gene expression of pro-inflammatory mediators, and increased
the expression of the T regulatory cell marker, Forkhead box-P3 (FoxP3) [50]. Our findings not only
demonstrated a direct impact of vitamin D on the degree of inflammation and secondary brain injury
that developed following stroke, but indicated that acute calcitriol supplementation can actually limit
the resulting injury, even in vitamin D-sufficient individuals [50].
3. Antioxidant Properties of Vitamin D
Among its potential pleiotropic roles in human health, it has been suggested that the active
form of vitamin D may act as a membrane antioxidant, protecting cell membranes against free
radical-induced lipid peroxidation through interaction with phospholipid fatty acid side chains,
in order to increase stabilization of the membrane structure [73]. Indeed, there is evidence that
vitamin D can be as effective as vitamin E, a major dietary lipid-soluble antioxidant, in reducing lipid
peroxidation and inducing the activity of reactive oxygen species (ROS) scavenging enzymes, such as
superoxide dismutase (SOD) [74]. Moreover, it has been reported that vitamin D can stimulate sirtuin
1 (SIRT1), a protein deacetylase known to exert cardioprotective effects, by increasing autophagy
and mitochondrial function via inhibition of the mTOR pathway and reducing oxidative stress and
inflammatory responses, via activation of FoxO-dependent antioxidant pathways and inhibition
of NF-κB signaling, respectively [75–78]. Furthermore, vitamin D has been shown to exert an
antioxidant role by VDR-mediated transcriptional downregulation of NOX2, a major isoform of
NADPH oxidase [79], and upregulation of Nrf2, a master inducer of antioxidant responses [80–82]
(Figure 2B). Such an action is consistent with the upregulation of critical biomarkers of oxidative stress,
including 8-hydroxy-2’-deoxyguanosine (8-OHdG) observed in VDR knockout mice [83].
More generally, it appears that vitamin D acts as a guardian of cellular homeostasis and protects
from oxidative stress in various cell types, including human endothelial cells, through its ability to
regulate crosstalk between redox signaling and autophagy [27,28,38,84]. Accordingly, whereas it is
now well-established that autophagy serves as an essential cellular antioxidant system by removing
damaged or dysfunctional proteins and organelles [40,41,85], endothelial cell viability can be enhanced
by pre-treatment with vitamin D before the induction of oxidative stress [27]. Furthermore, despite some
controversy over the clinical relevance of the antioxidant properties of vitamin D [86], recent studies
have shown that vitamin D supplementation increases basal levels of autophagy and decreases oxidative
stress parameters, suggesting a therapeutic potential in oxidative stress-related diseases [39,85,87–92].
Indeed, vitamin D is known to exert antioxidant properties in the endothelium [27,93,94], and vitamin
D supplementation is reported to decrease the burden of pathological vascular phenotypes related to
oxidative stress in a mouse model of a cerebrovascular disease [95].
Nevertheless, an individual’s response to a given dose of vitamin D may be influenced by multiple
factors, including genetic modifiers, as analysis of primary tissues from vitamin D intervention studies
have indicated large interindividual variation for the efficacy of vitamin D supplementation, an issue
that should be carefully considered in clinical management [12,96–98].
4. Determinants of Vitamin D Status and Related Health Outcomes
Serum concentration of 25(OH)D, the main circulating metabolite of vitamin D, is the best indicator
of vitamin D status, as it has a quite long half-life of 15 days and reflects both cutaneous synthesis
and dietary intake from foods and supplements. In contrast, circulating 1,25(OH)2D is generally
not considered a good biomarker of vitamin D status, mainly because it has a short half-life of
15 h, and its levels do not reflect strictly cutaneous synthesis and dietary intake. Although there is
currently no worldwide consensus on the optimal vitamin D status, serum 25(OH)D levels ≥ 75 nmol/L
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(≥ 30 ng/mL) are generally considered adequate for overall health, whereas levels between 50 and
75 nmol/L (20–30 ng/mL) indicate “insufficiency”, and levels < 50 nmol/L (< 20 ng/mL) indicate
“deficiency”. On the other hand, there is emerging evidence that serum 25(OH)D concentrations
> 150 nmol/L (> 60 ng/mL) are associated with potential adverse effects [99,100].
Multiple factors, including environmental and genetic determinants and their interactions, account
for variation in serum 25(OH)D levels and health consequences. The main source of vitamin D is
cutaneous biosynthesis induced by skin exposure to UVB light from the sun. Thus, baseline levels of
serum 25(OH)D can vary significantly according to both seasonal and geographical variations, and
are typically lower at the end of winter, especially when living at high latitudes (greater than 37th
parallel north or south of the equator). Indeed, people who live in the far northern and southern
hemispheres often cannot make any vitamin D3 in their skin for up to 6 months of the year, and are
therefore at relatively greater risk for vitamin D deficiency [101,102]. However, intake of recommended
dietary allowance (RDA) levels of vitamin D from foods or supplements, as well as established food
fortification programs, such as those in Finland, Sweden, the United States, Canada, and Australia, can
completely compensate for the lack of cutaneous vitamin D biosynthesis due to insufficient sunlight
exposure [102–106]. More generally, several recommendation-setting bodies have provided guidelines
for the maintenance of optimal vitamin D status and the treatment of vitamin deficiency, suggesting
that ≥ 75 nmol/L (≥ 30 ng/mL) is the optimal baseline 25(OH)D concentration to be maintained during
the year through adequate dosage regimens of vitamin D intake from food or supplements, in order to
prevent a drop below 50 nmol/L due to seasonal and geographical influences [99].
Besides seasonal, geographic, and lifestyle variations, a further factor that impinges on circulating
25(OH)D levels is the skin pigmentation-related efficiency of sunlight-induced vitamin D production.
Indeed, high levels of the protective skin-darkening pigment melanin reduce the skin’s ability to
produce vitamin D from sunlight. Consistently, there is evidence that skin color change between
summer and winter predicts seasonal 25(OH)D change [104,107], as well as that much of the variation
in serum 25(OH)D concentration between racial/ethnic groups may be attributed to skin color [108].
Overall, sun exposure, vitamin D intake, demographics, and lifestyle, as well as their potential
interactions, are important determinants of vitamin D status, and could therefore have a significant
impact both on its role in pathophysiological mechanisms and its therapeutic applications.
Regarding genetic determinants, numerous genome-wide association studies (GWAS) have
identified multiple genetic modifiers of vitamin D serum levels and biological effects, including
single-nucleotide polymorphisms (SNPs) in genes coding for key proteins involved in vitamin D
metabolism, transport, and signaling, which could be considered in the clinical management with
vitamin D. In particular, various polymorphisms in genes encoding 7-dehydrocholesterol reductase
(DHCR7, which shunts vitamin D precursors toward cholesterol biosynthesis); cytochrome P450
vitamin D hydroxylases, including CYP2R1 (25-hydroxylase), CYP27B1 (1α-hydroxylase), and CYP24A1
(24-hydroxylase); vitamin D binding protein (VDBP, also known as GC globulin); and vitamin D
receptor (VDR) were found to be statistically significantly associated with inter-individual variations in
serum 25(OH)D and 1,25(OH)2D levels, either at baseline or after vitamin D supplementation [109,110],
as well as with susceptibility to various human diseases [98,110–114]. More specifically, distinct
randomized controlled trials (RCTs) and systematic reviews/meta-analyses have shown that genetic
variants in CYP2R1 (rs10766197, rs10741657, rs12794714, rs1562902, rs2060793), CYP24A1 (rs2209314,
rs2762939, rs6013897), and VDBP (rs7041, rs4588) are either associated with baseline serum 25(OH)D
levels or modify the efficacy of vitamin D supplementation in increasing such levels [109,110,114–116].
On the other hand, polymorphisms in CYP27B1 (rs703842, rs10877012, rs4646536) and VDR (rs2228570,
rs7975232, rs1544410) were most commonly reported to be associated with health outcomes, including
susceptibility to metabolic, inflammatory, autoimmune, and infectious diseases [98,110–112,116].
While further validation studies with large sample sizes and controlled confounding factors
are still needed, these findings point to a potential interplay between vitamin D deficiency and
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polymorphisms in vitamin D-related genes, suggesting important implications for achieving optimal
vitamin D status and health outcomes in individuals with different genetic backgrounds.
Overall, genetic and nongenetic determinants of vitamin D status are significant predictors of
its health outcomes, and may have an important impact on susceptibility to various human diseases.
Indeed, there is already clear evidence that both seasonal variations and genetic modifiers of vitamin D
metabolism and functions are independently associated with inter-individual variability with regard
to the risk of developing cardiovascular disorders, including severe cerebrovascular diseases [117,118],
as described in more detail below.
5. Vitamin D Deficiency and Its Impact on Cerebrovascular Diseases
It is noteworthy that a meta-analysis of pooled data from 32 studies recently found that serum
25(OH)D concentrations < 30 ng/mL were associated with higher all-cause mortality than concentrations
> 30 ng/mL [119]. Specifically, despite some conflicting results, there is evidence that low solar UVB
exposure and low serum 25(OH)D levels are associated with an increased risk of CVD, as well
as that CVD mortality is about double in older individuals with deficient 25(OH)D concentrations
compared with age-matched individuals with adequate 25(OH)D concentrations (> 30 ng/mL) [120–124].
Indeed, accumulating evidence suggests that vitamin D insufficiency or deficiency may adversely
affect the cardiovascular system through multiple effects. Levels of the pro-hormone cholecalciferol
are maintained either through dietary consumption or epidermal synthesis following exposure to
ultraviolet light [125]. Nonetheless, “vitamin D insufficiency”, defined as 20–29 ng/mL of serum
25(OH)D, is endemic in humans, with more than a billion people affected worldwide, and may
require public health actions, such as systematic vitamin D food fortification [106,126]. Moreover,
“vitamin D deficiency” (< 20 ng/mL) is prevalent in almost half of the healthy population of developed
countries [126,127], is common in patients with CVD [127], and is independently associated with a
higher risk for future cardiovascular events [126,128]. Furthermore, vitamin D deficiency is likely to
be associated with advanced age, darker skin pigmentation, less sunlight exposure, and low dietary
intake of vitamin D [129], and has been linked to an increased risk of age-related morbidities that
include neurodegenerative diseases and cerebrovascular dysfunctions [130–132].
Epidemiological evidence suggests an association of vitamin D insufficiency with endothelial
dysfunction in healthy and pathological conditions [133,134]. Indeed, calcitriol acts as a direct
transcriptional regulator of endothelial nitric oxide (NO) synthase (eNOS), and can promote
normalization of eNOS mRNA expression and enzymatic activity in experimental atherosclerosis [135].
Mice carrying mutated, functionally inactive VDR exhibit increased arterial stiffness, endothelial
dysfunction, and lower NO bioavailability due to reduced eNOS expression [136]. Mice with
endothelial-specific deletion of the VDR exhibit reduced eNOS expression, impaired endothelium-
dependent vasorelaxation, and an augmented pressor effect of angiotensin II [137]. Furthermore,
vitamin D can exert powerful immunomodulatory actions to modify the immune response to injury
during various diseases, including atherosclerosis [64,138], cancer [25], asthma [139], and stroke [50].
In particular, vitamin D can attenuate inflammatory responses and promote protein homeostasis
via modulating the NF-κB and unfolded protein response (UPR) pathways, respectively [140,141].
In addition, vitamin D can regulate matrix homeostasis through the modulation of distinct matrix
metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) [142], consistent with its
deficiency being critical in major cerebrovascular diseases, including brain aneurysms, cerebrovascular
malformations, and stroke, where matrix destabilization is significant [118,143,144]. Overall, it is
plausible that the impaired endothelial function that may accompany low circulating vitamin D levels
contributes to an increased risk of cerebrovascular diseases and mortality. Indeed, there is increasing
interest in how vitamin D levels might influence the onset and severity of cerebrovascular diseases,
including stroke [145–150] and cerebrovascular malformations [43,95,117,128,151,152].
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5.1. Vitamin D Deficiency and Stroke
Stroke is a crippling cardiovascular event that accounts for 5–10% of all deaths, and is the leading
cause of serious long-term disability, with > 50% of survivors discharged into care [153]. About 85%
of strokes are caused by a clot formed in a cerebral artery in which a dysfunctional endothelium
would be typically present [153,154]. Vitamin D deficiency is particularly frequent in people who
have suffered a stroke, which is commonly associated with advanced age, limited mobility, decreased
sunlight exposure, and higher prevalence of malnutrition [155]. Meta-analyses have found that a
low vitamin D level contributes to a ~50% increased risk of incident stroke [156], and that there is a
stepwise increase in stroke risk with decreasing plasma vitamin D level [145].
Clinical vitamin D status appears to influence the incidence, impact, and recovery from ischemic
stroke. Vitamin D deficiency was recently found to be a risk factor for incident stroke, and the
strength of this association does not appear to differ by race [157,158]. Strikingly, in a prospective
study of 58,646 healthy adults with median follow-up period of 19.3 years, vitamin D intake was
inversely associated with the risk of mortality from stroke [159]. Furthermore, low serum levels of
vitamin D at admission have been proposed as an independent prognostic biomarker for greater stroke
severity [160,161], a larger infarct volume in the acute phase [162], a poorer functional outcome at
discharge [160,161], a higher incidence of cognitive impairment at one month [150], a higher risk of
death at one or two years [160,163], and a greater risk of early recurrent stroke [149,163]. There is
also evidence that high circulating levels of vitamin D are associated with less cognitive impairment
among stroke patients, manifested as greater functional improvement during rehabilitation [147,164].
The relationship between plasma vitamin D levels and functional outcome from stroke also applies
to patients who have received intravenous thrombolysis [148], consistent with the possibility that
improving vitamin D status after stroke might provide benefits in addition to those from reperfusion.
In a prospective population-based study of > 9300 participants, an association was found between
vitamin D and prevalent stroke, but only severe vitamin D deficiency was associated with incident
stroke, with the authors concluding that lower vitamin D levels may not lead to a higher stroke risk,
but may instead be a consequence of stroke [165].
Furthermore, there is evidence that a sufficient level of vitamin D could exert several
neuroprotective actions, including reduction of oxidative stress [166], regulation of neuronal
inflammation and death from stroke [50], and fewer neurogenerative disorders [167]. These findings
raise the possibility that low vitamin D serum levels, a treatable risk factor, might be targeted for
the reduction of disability among stroke sufferers. Indeed, a study to assess the long-term effect
of supplementation of vitamin D in ischemic stroke patients with low vitamin D levels found a
significant improvement in the outcome after three months [168]. Nevertheless, the value of vitamin D
supplementation in preventing stroke is still unclear, as a recent meta-analysis of randomized clinical
trials conducted in more than 80,000 patients found no clinical benefit of vitamin D supplementation in
reducing the incidence of (as opposed to outcome from) major cardiovascular events, including stroke
and cardiovascular death [169]. Therefore, it is possible that vitamin D supplementation is less effective
for preventing cardiovascular events than for limiting post-stroke injury and improving outcome.
5.2. Vitamin D Deficiency and CCM Disease
Cerebral cavernous malformation (CCM), also referred to as cavernous angioma or cavernoma, is
a significant vascular disease of genetic origin. CCM lesions mostly occur within the central nervous
system, and involve closely clustered, abnormally dilated and leaky capillaries, which are characterized
by a thin endothelium devoid of normal vessel wall components [43,170]. These lesions have a
prevalence of 0.5% in the general population, and can be detected by magnetic resonance imaging
(MRI) as single or multiple mulberry-like vascular sinusoids of varying size and locations. Most CCM
lesions are clinically and biologically inactive; however, in 30% of cases, they result in various clinical
symptoms, including focal neurological deficits, recurrent headaches, stroke, intracerebral hemorrhage
(ICH), and seizures. Clinical presentation can occur at any age and at varying levels of severity.
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Genetic studies in CCM patient cohorts have led to the identification of three disease genes,
CCM1/KRIT1, CCM2, and CCM3, which have been implicated in all major mechanisms of vascular
integrity maintenance and endothelial barrier function, including the coordination of redox signaling
and autophagy governing cell homeostasis and stress responses [43,171–180]. Consistent with such
pleiotropic functions, accumulated evidence from animal models and patient cohorts has demonstrated
that loss-of-function mutations of CCM genes only predispose to the development of CCM disease.
CCM may eventually occur with incomplete penetrance and highly variable expressivity, depending on
additional local factors, such as oxidative stress, inflammation, and sensitivity to stress [43,118,180,181].
Vitamin D deficiency is one of the risk factors that may impact the susceptibility to local oxidative
stress and inflammation, and thereby health outcomes for vulnerable carriers of mutations in CCM genes.
Indeed, whereas meta-analyses of general observational studies have consistently associated vitamin D
deficiency with an increased risk for inflammatory and CVDs [120,182–186], specific epidemiological
studies have shown that vitamin D serum levels, including throughout their seasonal variation,
are negatively associated with risk for CCM disease onset and severity [117,151,152]. Moreover,
a genome-wide association study (GWAS) in a large cohort of CCM patients sharing a common founder
mutation in the KRIT1 gene (Q455X) identified a correlation between CCM disease severity and SNPs
in genes involved in vitamin D metabolism and function, including CYP and MMP family members.
This suggested that SNPs in these genes can act as genetic susceptibility factors and modifiers of
CCM disease penetrance and expressivity [118]. In particular, CYP27A1 and CYP27B1, two essential
players in the vitamin D signaling system [187,188], were among the putative genetic modifiers of the
CYP family that appear to influence interindividual differences in the susceptibility to develop the
most severe disease phenotypes [118]. Furthermore, whereas various vascular protective actions of
vitamin D have been shown [27,120,128], an unbiased screening strategy for identifying repurposed
drugs for CCM disease treatment has led to the discovery of vitamin D as a major preventive and
therapeutic candidate, along with tempol (a scavenger of superoxide) [95]. In particular, as both
compounds were effective in decreasing cerebrovascular lesion burden in a mouse model of CCM
disease by ≈ 50%, it was suggested that their effectiveness was related to their shared ability to
promote endothelial stability through specific antioxidant, anti-inflammatory, and pro-autophagic
activities [43,95,128,173–175]. Indeed, as mentioned above, vitamin D can enhance endothelial barrier
function and inhibit peripheral vascular diseases by stimulating autophagy and limiting oxidative stress
and inflammatory events, including the production of ROS, lipopolysaccharides, and inflammatory
cytokines [27,35,93,94,128,189,190].
Thus, the emerging evidence indicates that defective autophagy and redox imbalance play a
major role in the genesis and progression of CCM lesions [43,175,180], as well as that vitamin D exerts
significant protective effects by counteracting such pathogenetic mechanisms [43,95,174,175]. Taken
together, these findings suggest that vitamin D should be considered within the recently proposed drug
combination therapy approaches aimed at gaining additive or synergistic effects for a more effective
treatment of CCM disease and associated comorbidities [180,191,192].
6. Conclusions and Perspectives
There is now considerable evidence that, besides regulating calcium homeostasis, vitamin D
influences other fundamental biological processes, such as autophagy, mitochondrial function, redox
homeostasis and signaling, epigenetic changes, and oxidative stress and inflammatory responses.
Serum vitamin D levels, as well as polymorphisms in VDR and CYP enzymes involved in the three
main steps of vitamin D metabolism (25-hydroxylation, 1α-hydroxylation, and 24-hydroxylation) [2],
have been increasingly associated with the incidence of various human diseases, including cancer and
inflammatory, autoimmune, and neurodegenerative diseases, as well as CVDs [35,98,116,193] This is
consistent with findings in VDR- and 1α-hydroxylase-deficient mice [194].
This review has focused on two of the major cerebrovascular diseases that are demonstrably
connected to vitamin D deficiency: stroke and CCM disease. We have highlighted underlying
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pleiotropic pro-oxidant and pro-inflammatory molecular mechanisms, as well as the likely importance
of maintaining an optimal vitamin D homeostasis for mitigating the inflammation–oxidative stress
cycle that may exacerbate these cerebrovascular diseases (Figure 3). Indeed, while vitamin D deficiency
is endemic in the population, it is easy to screen for and can be readily and inexpensively treated by
dietary supplementation and modest sunlight exposure. In particular, whereas a low serum level of
vitamin D is associated with higher risk of stroke and negatively impacts recovery and mortality from
stroke, preclinical data suggest that acute administration of vitamin D can limit infarct progression by
modulating post-stroke brain inflammation. Moreover, whereas it is now established that vitamin
D modulates endothelial homeostasis and barrier function [128], a potential benefit of vitamin D
in preventing or limiting the onset and severity of CCM disease has clearly emerged from both
epidemiological studies and animal models [43,95,117,151,152].
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Figure 3. Vitamin D deficiency and its impact on cerebrovascular diseases. Vitamin D deficiency may
adversely affect endothelial cell function and vascular homeostasis through pleiotropic pro-oxidant and
pro-inflammatory effects, including the downregulation of autophagy, unfolded protein response (UPR),
endothelial nitric oxide synthase (eNOS), sirtuin 1 (SIRT1), and tissue inhibitors of metalloproteinases
(TIMPs), as well as the upregulation of NADPH oxidases (NOXs), reactive oxygen species (ROS), nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB), inflammatory cytokines, and matrix
metalloproteinases (MMPs). In turn, these effects can promote pro-oxidant and pro-inflammatory
conditions, as well as an enhanced tissue sensitivity to oxidative stress and inflammatory events, with
consequent increased susceptibility to the onset and severity of cerebrovascular diseases, including
stroke and cerebral cavernous malformation (CCM) disease (see text for details).
On the other hand, the therapeutic effect of vitamin D supplementation remains controversial,
as there is still some inconsistency in the conclusions of distinct RCTs and meta-analyses concerning
its beneficial effects on oxidative stress biomarkers and CVD outcomes, including stroke, or on
mortality [25,119,159,161,168,169,195–199]. Such controversy is akin to that regarding the putative
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beneficial effects of antioxidants in optimizing health [200], with the reported discrepancies likely due
to the complexity of the systems and existence of multiple confounding factors. Indeed, a careful
analysis of existing RTC and related meta-analysis studies on the effects of vitamin D supplementation
reveals several methodological limitations, including the use of diverse study populations, different
doses of vitamin D with or without Ca2+, different durations of supplementation and follow-up,
different baseline and acquired circulating 25(OH)D concentrations, and different study outcome
parameters [99,201]. Furthermore, significant discrepancies could result from the large inter-individual
variation in genetic determinants of the efficacy of vitamin D supplementation [12,109,110], as well
as its context-dependent effects on mechanisms in endothelial cells, including autophagy [202].
Consistent with these potential shortcomings in evaluating the effects of vitamin D supplementation,
there remains much controversy and an open debate about the reliability of either RCTs or their
meta-analyses [99,203,204].
In contrast, the outcomes of a large number of experimental studies have consistently shown
that vitamin D influences most of the risk factors and molecular mechanisms associated with CVDs,
suggesting that its use in the clinical setting should be considered for the prevention of the onset,
progression, and severity of these diseases.
In conclusion, while the benefit of vitamin D supplementation on cerebrovascular outcome
requires deeper study, it may represent a novel approach for limiting the overall impact of acute stroke
and CCM disease. Therefore, we suggest that it is now essential both to implement accurate screenings
and large, well-powered RCTs for investigating vitamin D deficiency and supplementation in stroke
and CCM patients, in order to more fully characterize the molecular mechanisms underlying the
effects of vitamin D. In particular, a better understanding of the emerging major role of autophagy in
the multiple health-promoting effects of vitamin D [28] is needed, as well as the role of factors that
influence the activity of CYP vitamin D-metabolizing hydroxylases and local production of vitamin D’s
hormonally active form, calcitriol [1,2]. Such knowledge may lead to the design of drug combinations
and multitargeting therapeutic strategies for the more effective treatment of diseases associated with
vitamin D deficiency.
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